Sagimet Biosciences Inc. (SGMT) Income Statement
SGMT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSGMT revenue and net income
SGMT profit margins
SGMT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SGMT quarterly EPS vs estimates
Sagimet Biosciences beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.25).
SGMT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2.0M | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | $0 | $130,000 | $134,000 | $124,000 | $88,000 |
| Gross profit | — | — | $2.0M | −$130,000 | −$134,000 | −$124,000 | −$88,000 |
| Research & development | $39.1M | $38.4M | $19.8M | $24.9M | $19.3M | $8.2M | $8.4M |
| Sales, general & admin | $17.8M | $16.0M | $13.0M | $6.1M | $4.4M | $3.2M | $5.9M |
| Total operating expenses | $56.9M | $54.5M | $32.7M | $31.1M | $23.7M | $11.4M | $14.1M |
| Operating income | −$56.9M | −$54.5M | −$30.7M | −$31.1M | −$23.7M | −$11.4M | −$14.2M |
| Interest income | $5.9M | $8.9M | $1.7M | $553,000 | $26,000 | $30,000 | $128,000 |
| Interest expense | — | — | — | — | — | $0 | $64,000 |
| Income before taxes | −$51.0M | −$45.6M | −$27.9M | −$30.5M | −$24.4M | −$11.4M | −$14.3M |
| Income taxes | — | — | −$2.9M | −$31.6M | −$23.7M | −$176,297 | −$9,000 |
| Net income | −$51.0M | −$45.6M | −$27.9M | −$30.5M | −$24.4M | −$11.4M | −$14.3M |
| EBITDA | −$51.0M | −$45.6M | −$27.9M | −$31.1M | −$23.7M | −$11.4M | −$14.1M |
| EPS (diluted) | −$1.57 | −$1.43 | −$37.37 | −$1.38 | −$1.10 | −$0.51 | — |
| Gross margin | — | — | 100.0% | — | — | — | — |
| Operating margin | — | — | −1,537.0% | — | — | — | — |
| Net margin | — | — | −1,393.8% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.0M |
| Cost of revenue | — | — | — | — | — | — | — | — | — | — | — | $35,000 |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | $2.0M |
| Research & development | $11.5M | $7.0M | $6.7M | $9.7M | $7.2M | $15.3M | $14.2M | $12.7M | $6.3M | $5.3M | $5.7M | $5.0M |
| Sales, general & admin | $4.3M | $4.7M | $4.0M | $4.6M | $4.7M | $4.5M | $4.0M | $4.2M | $4.3M | $3.5M | $3.8M | $4.5M |
| Total operating expenses | $15.8M | $11.7M | $10.8M | $14.3M | $11.9M | $19.9M | $18.2M | $16.9M | $10.6M | $8.8M | $9.5M | $9.5M |
| Operating income | −$15.8M | −$11.7M | −$10.8M | −$14.3M | −$11.9M | −$19.9M | −$18.2M | −$16.9M | −$10.6M | −$8.8M | −$9.5M | −$7.5M |
| Interest income | $1.9M | $1.1M | $1.2M | $1.4M | $1.5M | $1.7M | $2.0M | $2.3M | $2.5M | $2.1M | $1.3M | $1.1M |
| Income before taxes | −$14.0M | −$10.7M | −$9.6M | −$12.9M | −$10.4M | −$18.2M | −$16.2M | −$14.6M | −$8.1M | −$6.6M | −$8.2M | −$6.4M |
| Income taxes | — | — | — | — | — | — | — | — | −$10.6M | −$8.8M | −$1.3M | −$1.1M |
| Net income | −$14.0M | −$10.7M | −$9.6M | −$12.9M | −$10.4M | −$18.2M | −$16.2M | −$14.6M | −$8.1M | −$6.6M | −$8.2M | −$6.4M |
| EBITDA | −$14.0M | −$10.7M | −$12.2M | −$12.9M | −$10.4M | −$18.2M | −$16.2M | −$14.6M | −$8.1M | $2.1M | $1.3M | −$6.4M |
| EPS (diluted) | −$0.26 | −$0.33 | −$0.29 | −$0.40 | −$0.32 | −$0.56 | −$0.50 | −$0.45 | −$0.25 | −$0.23 | −$0.78 | −$0.35 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | 100.0% |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — | −372.6% |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | −317.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SGMT's financial statements (latest annual report filed March 11, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SGMT financial results
Sagimet Biosciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $51.0 million. Diluted earnings per share came to −$1.57.
See the SGMT stock overview for the latest quote and news, or the SGMT chart for price history and technical indicators.
SGMT income statement FAQ
Does Sagimet Biosciences have revenue?
Sagimet Biosciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Sagimet Biosciences profitable?
No. Sagimet Biosciences reported a net loss of $51.0 million in fiscal 2025.
How much does Sagimet Biosciences spend on research and development?
Sagimet Biosciences spent $39.1 million on research and development in fiscal 2025.
What are Sagimet Biosciences's earnings per share?
Sagimet Biosciences earned $-1.57 per diluted share in fiscal 2025, compared with $-1.43 a year earlier.
When will Sagimet Biosciences report its next earnings?
Sagimet Biosciences is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens.
When does Sagimet Biosciences's fiscal year end?
Sagimet Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 11, 2026.